Navigation Links
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2013 On August 7, 2013
Date:7/29/2013

BOULDER, Colo., July 29, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:   ARRY) will report financial results for the fourth quarter and full year of fiscal 2013 on Wednesday, August 7, 2013 and hold a conference call to discuss those results on Thursday, August 8, 2013.  Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.

(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Conference Call InformationDate:Thursday, August 8, 2013Time:9:00 a.m. eastern timeToll-Free:(800) 447-0521Toll:(847) 413-3238Pass Code:35320184Webcast, including Replay and Conference Call Slides:  http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.
Novartis began a Phase 3 trial evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and expects to begin a Phase 3 trial in patients with BRAF-mutant melanoma in 2013.  In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013.  AstraZeneca began a pivotal trial with Array-invented selumetinib in patients with thyroid cancer in May 2013 and expects to begin a Phase 3 trial in patients with non-small cell lung cancer in 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.

CONTACT:

Tricia Haugeto Array BioPharma Inc.(303) 386-1193thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
2. Loxo Oncology And Array BioPharma Announce License And Collaboration Agreement
3. Array BioPharma To Present At The Wells Fargo Securities Research And Economics 2013 Healthcare Conference
4. Array BioPharma Announces Exercise Of Underwriters Option To Purchase An Additional $17.25 Million Of 3.00% Convertible Senior Notes
5. New Date And Time For Array BioPharma Presentation At The Jefferies 2013 Global Healthcare Conference
6. Array BioPharma Announces Proposed Public Offering of Convertible Debt
7. Two Array Invented MEK Inhibitors Showcased At ASCO
8. Array BioPharma To Present At The Jefferies 2013 Global Healthcare Conference
9. Oncothyreon and Array Announce Collaboration to Develop and Commercialize anti-HER2 Compound ARRY-380
10. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
11. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... , May 25, 2017  In response to ... , Direct Relief is working with Pfizer to ... available at no cost to community health centers, free ... providers nationwide. "Pfizer has a long-standing ... medicines and ensuring patient safety through educational activities," said ...
(Date:5/18/2017)... 2017  Two Bayer U.S. Pharmaceutical leaders received top ... recent 28 th Woman of the Year ... HBA,s longstanding mission of furthering the advancement and impact ... Cindy Powell-Steffen , senior director of brand activation ... Libby Howe , a regional business manager for ...
(Date:5/11/2017)... May 11, 2017  Thornhill Research Inc. ( ... awarded an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract ... Canadian Commercial Corporation (CCC) ( Ottawa, Ontario, ... to administer general anesthesia to patients requiring emergency ... "The US Marine Corps have been a longtime ...
Breaking Medicine Technology:
(Date:5/26/2017)... , ... May 26, 2017 , ... ... announce a new educational seminar to focus on current legislative activity and the ... will begin at 1 p.m. Sunday, Sept. 10, and will continue through Monday, ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of ... the healthiest seniors are located in the Midwest. With the average cost of healthcare ... people are concerned with both the quality and affordability of where they live. An ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the Congressional Budget ... the U.S. House on May 4, would result in 23 million Americans losing their ... of the 2010 Patient Protection and Affordable Care Act (ACA). , “It is ...
(Date:5/26/2017)... ... May 26, 2017 , ... Silver Birch of Hammond, ... is located on more than four acres of land at 5620 Sohl Avenue in ... The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each of the private ...
(Date:5/26/2017)... ... ... “When the Stars Lead Home”: a poignant story of loss, determination, and ... Douglas, an avid reader who lives in the Pacific Northwest with her husband, daughter, ... Adventure Camp. She couldn’t be more grateful. , Twelve-year old Tizzy could not believe ...
Breaking Medicine News(10 mins):